Pharma Mar (XMAD:PHM) FCF Margin % : 5.31% (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Pharma Mar FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pharma Mar's Free Cash Flow for the three months ended in Mar. 2024 was €2.0 Mil. Pharma Mar's Revenue for the three months ended in Mar. 2024 was €38.0 Mil. Therefore, Pharma Mar's FCF Margin % for the quarter that ended in Mar. 2024 was 5.31%.

As of today, Pharma Mar's current FCF Yield % is -5.52%.

The historical rank and industry rank for Pharma Mar's FCF Margin % or its related term are showing as below:

XMAD:PHM' s FCF Margin % Range Over the Past 10 Years
Min: -32.83 Med: -1.47 Max: 102.21
Current: -21.45

During the past 13 years, the highest FCF Margin % of Pharma Mar was 102.21%. The lowest was -32.83%. And the median was -1.47%.

XMAD:PHM's FCF Margin % is ranked better than
68.83% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs XMAD:PHM: -21.45

Pharma Mar FCF Margin % Historical Data

The historical data trend for Pharma Mar's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar FCF Margin % Chart

Pharma Mar Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-32.83

102.21

7.78

15.01

-18.59

Pharma Mar Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															21.76	-36.56	-30.73	-20.71	5.31

Competitive Comparison of Pharma Mar's FCF Margin %

For the Biotechnology subindustry, Pharma Mar's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Mar's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Pharma Mar's FCF Margin % falls into.

Pharma Mar FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Pharma Mar's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-29.402	/	158.153
	=	-18.59 %

Pharma Mar's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	2.016	/	37.966
	=	5.31 %

Pharma Mar FCF Margin % Related Terms

Thank you for viewing the detailed overview of Pharma Mar's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Mar (XMAD:PHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (XMAD:PHM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

PHMMF:USA PHMe:UK 0RC6:UK

Address

Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770

Website

http://www.pharmamar.com

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.